Lonza Capabilities Update September 2026: ADC

Iwan Bertholjotti, Lonza's Senior Director of Commercial Development for Bioconjugates, will discuss how Lonza is expanding its bioconjugates capabilities to meet growing demand for seamless progression from clinical development to commercial manufacturing. He will show how Lonza's bioconjugation network — including new large-scale capacity in Visp, an enhanced payload portfolio, and expanded conjugation technologies — supports customers as they scale toward commercialization.

Iwan will also examine the critical role experienced CDMOs play in providing the capacity, expertise, and integrated capabilities that mitigate CMC and supply chain risks, simplifying the path to commercial success.